There is no standard procedure for the treatment of benign bone tumors. The bone defect following the curettage of the bone tumor can be filled with autologus bone marrow, polymethylmethacrylate cement, allograft, tricalcium phosphate, and demineralized bone matrix (DBM). All these procedures have their own advantages and disadvantages. Autografting is the gold standard in tumor surgery; nevertheless, its disadvantages including limited access, cosmetic problems, and donor site morbidity make the alternative treatment modalities as viable options. Resorption of graft material and transmission of disease are associated risks of allograft use.[1] Polymethylmethacrylate cement is non-biological and its Young’s modulus of elasticity is lower than cortical bone, responds to compression-distraction forces differently compared with cortical bone, and has poor tensile and shear strength.[2] Demineralized bone matrix is expensive and osteoinductive without structural support.[3]

Our hypothesis was that cement combined DBM treatment stimulates new bone formation, thus improves the functional scores. To the authors’ knowledge, no study has focused on this technique and searched the effect of new bone formation in the cortical window on functional outcomes. Therefore, in this study, we aimed to investigate the effectivity of cement combined DBM treatment on new bone formation in the cortical window as well as to evaluate the effect of new bone formation on functional outcomes.

**Objectives:** This study aims to investigate the effectivity of cement combined demineralized bone matrix (DBM) treatment on new bone formation in the cortical window as well as to evaluate the effect of new bone formation on functional outcomes.

**Patients and methods:** Thirty-two benign bone tumor patients (15 males, 17 females; median age 38 years; range, 12 to 68 years), who were treated with cement combined DBM between February 2010 and December 2014, were evaluated retrospectively. Patient characteristics were recorded as age, gender, tumor localization, histological diagnosis, Enneking stage, tumor size, size of the cortical window, usage of prophylactic fixation, time to return to work, Musculoskeletal Tumor Society (MSTS) functional score, tumor relapse, and new bone formation on the cortical window in the computed tomography scans after one year of surgery.

**Results:** Median tumor volume was 17.2 cm³ (range, 2.8 to 139.6 cm³), median area of the cortical window was 8.3 cm² (range, 1.6 to 28.4 cm²), and median postoperative one-year MSTS score was 84.5 (range, 66 to 97). MSTS scores were significantly worse with the usage of prophylactic fixation (p<0.001). There was a statistically significant difference between the usage of prophylactic fixation and cortical window size (p=0.013). There was a low-level negative correlation in terms of age and bone formation on the cortical window (p=0.046, r= -0.356) and mid-level negative correlation between cortical window size and functional scores (p=0.001, r= -0.577).

**Conclusion:** Application of cement combined with DBM procedure is an effective, alternative, and biological treatment in bone tumors that provides immediate stability and stimulates new bone formation on the cortical window.

**Keywords:** Benign bone tumor, cement, demineralized bone matrix.
PATIENTS AND METHODS

Thirty-two benign bone tumor patients (15 males, 17 females; median age 38 years; range, 12 to 68 years), who underwent cement combined DBM procedure at Bezmialem Vakif University School of Medicine between February 2010 and December 2014 and were followed up for a minimum of one year, were evaluated retrospectively. Patients with axial (n=2), pelvic bone tumors (n=3), metastatic giant cell bone tumor (n=2), or those who underwent adjuvant radiotherapy or chemotherapy (n=1) or were followed up for less than one year (n=11) were excluded. The study protocol was approved by the Bezmialem Vakif University School of Medicine Ethics Committee. A written informed consent was obtained from each patient. The study was conducted in accordance with the principles of the Declaration of Helsinki.

The mean follow-up time was 20.8±7.7 months. There were simple bone cysts (n=6, 19%), enchondromas (n=14, 43%), aneurysmal bone cyst (n=1, 3%), fibrous dysplasia (n=3, 9%), chondroblastomas (n=2, 6%), and giant cell bone tumors (n=6, 19%) according to the pathology results.

The lesions were located at the proximal humerus (n=5), proximal femur (n=3), distal femur (n=16), proximal tibia (n=5), distal tibia (n=1), and calcaneus (n=2). There were three (9%) Enneking stage I, 16 (50%) stage II, and 13 (41%) stage III patients.

All patients were examined through direct X-ray, computed tomography (CT), and magnetic resonance imaging (MRI) for preoperative surgical planning. All operations were performed by the same experienced tumor surgeon and the operation procedure was similar. A tourniquet was used in all patients if tumor localization allowed. Generally, an adequate longitudinal incision was performed over the lesion to dominate the whole lesion. An oval cortical window was created with a drill and osteotome. The cortical window and affected soft tissue on the cortex were removed. After an extensive curettage was performed, mechanical cleaning was carried out with a high-speed burr. If necessary, the cavity was rinsed with phenol and ethanol solution while preserving the surrounding soft tissue. Then, antibiotic-free bone cement was prepared and the cavity was filled with high viscosity bone cement (Biomet Bone Cement R, Biomet Orthopedics GmbH, Ried, Switzerland). Grooves were created with a scalpel on the surface of cement to increase the cement-graft retention. Thereafter, when the cement was solidified, putty form of DBM (Grafton, Osteotech Inc., Eatontown, NJ, USA) was applied with at least one standard cortical thickness on the cement (Figure 1). Prophylactic osteosynthesis was performed in patients with possible pathological fracture.

Tumor volume \[\text{volume} = \frac{4}{3}\pi(D1/2)(D2/2)(D3/2)\] was calculated according to the direct preoperative X-rays and CT sections. Patients were routinely controlled with direct radiography every three months for the first year. To assess tumor recurrence and bone regeneration on the cortical window, all patients were evaluated with CT scans in the first postoperative year (Figure 2). As there is no defined classification method in the literature, we used our own methodology to classify the amount of new bone formation on the cortical window regarding CT scans (Table I). Every measurement on radiological

![FIGURE 1. (a) Appearance of tumor after cortical window removal. (b) Bone defect following curettage and burr application. (c) Filled bone defect with cement. (d) View after application of demineralized bone matrix minimally one bone cortex thickness on cement.]
images was performed by a radiologist three times to reduce the dating error. Musculoskeletal Tumor Society (MSTS) functional scores of all patients were performed in the first postoperative year.\(^5\)

The relationship between new bone formation on the cortical window, age, Enneking tumor stage, functional score, time to return work, size of the cortical window (cm\(^2\)), tumor size (cm\(^3\)), and usage of prophylactic fixation were evaluated.

**Statistical analysis**

Statistical analysis of the data was performed using the IBM SPSS version 21.0 software (IBM Corp., Armonk, NY, USA). Concordance of the continuous data to normal distribution was tested by Shapiro-Wilk test. Continuous variables were expressed with median (minimum-maximum) and mean ± standard deviation values and categorical variables were expressed with frequency (percentage) values. Two group comparisons were performed using the Mann-Whitney U test; independent sample t-test and three group comparisons were performed using the Kruskal-Wallis and one-way analysis of variance tests. The relationship between non-normally distributed variables was investigated by Spearman’s correlation coefficient. Results were reported with 95% confidence intervals (CI) and related p values. P<0.05 was considered as statistically significant.

**RESULTS**

The median size of the cortical window to reach the tumor was 8.3 cm\(^2\) (range, 1.6 to 28.4 cm\(^2\)), while the median tumor volume was 17.2 cm\(^3\) (range, 2.8 to 139.6 cm\(^3\)). The median time to return to work was 60 days (range, 15 to 220 days). The median new bone formation on the cortical window was grade II.

Ten patients’ cortical windows were totally healed with the new bone formation (grade IV) and three patients’ cortical windows were healed more than a half (grade III) (Figure 3). The median MSTS score was 84.5 (range, 66 to 97). Nine patients (28%) underwent prophylactic stabilization.

There was no statistically significant difference between tumor size and prophylactic fixation.
(p=0.592). However, there was a statistically significant difference between prophylactic fixation and cortical window (p=0.013). There was no significant difference between the usage of prophylactic fixation and new bone formation on the cortical window (p=0.967). Postoperative first year MSTS score was found statistically worse in patients with prophylactic fixation (p<0.001).

There was a weak negative correlation between age and new bone formation (p=0.046, r=-0.356). There was a moderate negative correlation between the return time to work and MSTS score (p=0.004, r=-0.498). There was a moderate negative correlation between cortical window and MSTS score (p=0.001, r=-0.577). There was no correlation between age and MSTS score (p=0.223), tumor volume and MSTS score (p=0.771), new bone formation and cortical window size (p=0.692), new bone formation and MSTS score (p=0.964), the return time to work and new bone formation on cortical window (p=0.398).

Local recurrence happened only in one patient, who had giant cell bone tumor. After aggressive curettage, revision surgery was performed by applying DBM over the cement, as the same procedure. None of the patients had any other complications such as infection, pathological fracture, seroma or hematoma.

**DISCUSSION**

The usage of cement in bone tumors provides immediate structural support to bone and absorbing stress. Thermal cytotoxic effect of the cement reduces the local recurrence.[6] Cement reconstruction is a successful method in bone tumors because it provides mechanical support and reduces the possibility of pathological fracture. Therefore, it is more preferable than graft in the load bearing, high stress regions, and large defects.[7] Its simple reconstruction procedure, satisfactory functional and radiological results as well as low-cost increase the range of usage.[8]

Deminerlized bone matrix is an alternative allograft product for filling bone defects, which provides bone regeneration mainly through osteoconduction and partly osteoinduction.[9] In recent years, the treatment of benign bone tumors with DBM has become popular in orthopedic and maxillofacial surgery due to its high recovery and low complication rates.[10,11] Therefore, it has increased its combined use of other graft materials. There are two level 3[12,13] and three level 4 studies,[14-16] which show that combined DBM and autologous bone marrow use is effective in the treatment of active bone cysts. Successful results have been also shown with the use of DBM in combination with steroids.[17] Teng et al.[18] reported that the combined use of allograft and cement in giant-cell bone tumors around the knee has led to less mechanical failure and they suggest this method as an optimal reconstruction strategy. In the literature review, we could not find any data about the combined use of DBM and cement as well as the effect of new bone formation in cortical window on functional scores.[19] By the cement combined DBM treatment, we provide initial mechanical strength by taking advantage of the load-bearing effect of the cement which makes early weight bearing possible. Moreover, we optimize the cost effectiveness and reduce the possibility of graft resorption and fracture by using less DBM. In addition, we also increase cortical bone formation that carries the load on removed cortical window. In our study, we found that 3/32 patients had more than 50% new bone formation on the cortical window and the cortical window of 10/32 patients were almost completely healed with new bone in the first year CT scans. Although the efficacy of DBM to produce live bone is best demonstrated only by histological examination, the thin rim layer, which appears in tomography and direct graphs, shows an increased activity in the scintigraphy. The radiological and histological results are parallel to each other in experimental studies.[20] We did not find any correlation between the functional scores and new bone formation.

It is known that the effectiveness of different brands of DBMs varies from each other.[21] The reasons of different results have been shown such as the sterilization process, washing procedure, varying from donor to donor resulting in differences between products, inherent BMP types, and different amounts of graft.[22,23] The fact that the US Food and Drug Administration (FDA) is not performing standard controls for DBMs was shown to be not a surprise in the diversity of DBM results. We think that we have standardized and optimized our treatment, because we used same brand, which has shown superiority, and same form DBM.[21]

Traditionally, aging decreases mesenchymal cell differentiation, collagen activity, bone metabolism, and recipient aging declines the effect of allografts.[23] Also, there is an increased risk of non-union with elder population in DBM-treated patients with lumbar fusion.[24] We found a negative correlation between aging and new bone formation on cortical window consistent with the literature.

Prophylactic osteosynthesis is indicated to reduce the possibility of pathological fracture for bone tumors greater than 60 cm$^2$ and in the load bearing areas.[25,26] We did not find any correlation between
Use of cement combined grafting in bone tumors

8. Özter D, Er T, Aycan OE, Öke R, Coskun M, Kabukçuoglu YS. May bone cement be used to treat benign aggressive bone tumors of the feet with confidence? Foot (Edinb) 2014;24:1-5.